Immutep Ltd
eftilagimod alfa (efti)
non-small cell lung cancer (1L NSCLC)
Resolved
102days ago
FDA decision · Mar 27, 2026
What's at stake
The FDA's approval decision on eftilagimod alfa (efti) for non-small cell lung cancer (1L NSCLC) is due Mar 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 13h ago
“the FDA has set a PDUFA action date of March 27, 2026”